Prevalence of allergic bronchopulmonary aspergillosis/Aspergillus sensitization in chronic obstructive pulmonary disease: A systematic review and meta-analysis

IF 2.1 Q2 RESPIRATORY SYSTEM

Respiratory investigation Pub Date : 2026-07-01 Epub Date: 2026-06-26 DOI:10.1016/j.resinv.2026.101469

Anuj Ajayababu, Abin Antony, Bhoomit Goyal, Animesh Ray

{"title":"Prevalence of allergic bronchopulmonary aspergillosis/Aspergillus sensitization in chronic obstructive pulmonary disease: A systematic review and meta-analysis","authors":"Anuj Ajayababu, Abin Antony, Bhoomit Goyal, Animesh Ray","doi":"10.1016/j.resinv.2026.101469","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Although classically associated with asthma and cystic fibrosis, allergic bronchopulmonary aspergillosis (ABPA) is increasingly recognized in patients with other risk factors, including COPD. This systematic review synthesizes available evidence on the association between COPD and <em>Aspergillus</em> sensitization (AS)/ABPA to determine their prevalence.</div></div><div><h3>Methods</h3><div>PubMed, Embase, SCOPUS, and Web of Science databases were searched from inception to June 30, 2025, without language restrictions. Summary data from studies reporting the proportion of COPD patients with AS or ABPA were included, while individual case reports, studies reporting misdiagnosis and those without data on prevalence were excluded. The primary outcome assessed was prevalence of ABPA/AS in patients with COPD.</div></div><div><h3>Findings</h3><div>946 records were identified from the initial search. Overall 23 original studies, eight reporting prevalence of ABPA in 1529 COPD patients and 17 reporting AS in 3505 COPD patients were included in the meta-analysis. The pooled prevalence of ABPA and <em>Aspergillus</em> sensitization in COPD patients diagnosed based on spirometry criteria was 2.1% [95% CI: 0.1%-5.8%] and 10.4% [95% CI: 7.0%-14.3%] respectively. Overall estimates of both showed significant heterogeneity [I<sup>2</sup> = 63.7% for ABPA and 83.7% for AS]. Prevalence of ABPA was higher in studies [4.4% (95% CI: 2.7%-6.3%)] using IgE <em>Aspergillus</em> as entry criteria as compared to those using other tests (skin tests, total IgE) [1.3% (95% CI: 0.0%-5.1%)].</div></div><div><h3>Interpretation</h3><div>This systematic review highlights COPD as a potentially significant risk factor for both ABPA (∼2.1%) and <em>Aspergillus</em> sensitization (∼10.4%).</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 4","pages":"Article 101469"},"PeriodicalIF":2.1000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534526001036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Although classically associated with asthma and cystic fibrosis, allergic bronchopulmonary aspergillosis (ABPA) is increasingly recognized in patients with other risk factors, including COPD. This systematic review synthesizes available evidence on the association between COPD and Aspergillus sensitization (AS)/ABPA to determine their prevalence.

Methods

PubMed, Embase, SCOPUS, and Web of Science databases were searched from inception to June 30, 2025, without language restrictions. Summary data from studies reporting the proportion of COPD patients with AS or ABPA were included, while individual case reports, studies reporting misdiagnosis and those without data on prevalence were excluded. The primary outcome assessed was prevalence of ABPA/AS in patients with COPD.

Findings

946 records were identified from the initial search. Overall 23 original studies, eight reporting prevalence of ABPA in 1529 COPD patients and 17 reporting AS in 3505 COPD patients were included in the meta-analysis. The pooled prevalence of ABPA and Aspergillus sensitization in COPD patients diagnosed based on spirometry criteria was 2.1% [95% CI: 0.1%-5.8%] and 10.4% [95% CI: 7.0%-14.3%] respectively. Overall estimates of both showed significant heterogeneity [I² = 63.7% for ABPA and 83.7% for AS]. Prevalence of ABPA was higher in studies [4.4% (95% CI: 2.7%-6.3%)] using IgE Aspergillus as entry criteria as compared to those using other tests (skin tests, total IgE) [1.3% (95% CI: 0.0%-5.1%)].

Interpretation

This systematic review highlights COPD as a potentially significant risk factor for both ABPA (∼2.1%) and Aspergillus sensitization (∼10.4%).

查看原文本刊更多论文

慢性阻塞性肺疾病中过敏性支气管肺曲霉病/曲霉致敏的患病率：一项系统综述和荟萃分析

背景：虽然过敏性支气管肺曲霉病（ABPA）通常与哮喘和囊性纤维化相关，但在其他危险因素（包括COPD）患者中越来越多地被认识到。本系统综述综合了COPD与曲霉致敏(AS)/ABPA之间关系的现有证据，以确定其患病率。方法：检索PubMed、Embase、SCOPUS和Web of Science数据库，检索时间从建站到2025年6月30日，无语言限制。报告COPD患者合并AS或ABPA比例的研究汇总数据被纳入，而个别病例报告、报告误诊的研究和没有患病率数据的研究被排除。评估的主要结局是COPD患者中ABPA/AS的患病率。结果：从最初的搜索中确定了946条记录。荟萃分析纳入了23项原始研究，其中8项报告了1529名COPD患者的ABPA患病率，17项报告了3505名COPD患者的AS患病率。在肺活量测定标准诊断的COPD患者中，ABPA和曲霉菌致敏的总患病率分别为2.1% [95% CI: 0.1%-5.8%]和10.4% [95% CI: 7.0%-14.3%]。两者的总体估计均显示出显著的异质性[I2 = ABPA为63.7%，AS为83.7%]。与使用其他测试（皮肤测试，总IgE）的研究(1.3% （95% CI: 0.0%-5.1%）相比，使用IgE曲霉作为进入标准的研究中ABPA的患病率更高[4.4% (95% CI: 2.7%-6.3%)]。该系统综述强调COPD是ABPA（~ 2.1%）和曲霉致敏（~ 10.4%）的潜在重要危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊